Personal Genome Diagnostics has licensed exclusive rights to a technology known as PARE from Johns Hopkins University that is enabling the company to successfully analyze cell-free tumor DNA circulating in patients’ blood.
PGDx is now using PARE, other proprietary technologies such as Digital Karyotyping (DK), and the expertise and know-how of its scientists to routinely conduct genomic testing using samples from blood and other bodily fluids, thereby avoiding the need for tumor biopsies.
PARE (Personalized Analysis of Rearranged Ends) technology is an ultrasensitive technique that enables whole genome identification of changes in the tumor-specific DNA that is shed into the circulation of cancer patients.
PARE has already been successfully used to detect important cancer mutations such as amplifications in ERBB2 (HER2/neu), MET and CDK6 in the blood of cancer patients.
PGDx’s success in conducting these analyses using circulating tumor DNA from easily-obtained blood samples makes personalized treatment far more feasible.